Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 34
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Pak Med Assoc ; 74(6 (Supple-6)): S85-S87, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-39018147

RESUMEN

Some side effects regarding COVID-19 vaccination have been reported. The most common reports of cardiovascular issues were myocarditis and pericarditis. Although inflammation is the most common cause in this matter, there were only a few reports about ischaemic cases related to COVID-19 vaccines. These reports also commonly included older men who received a second dose of mRNA vaccination. We present a 25-year-old man with chest pain mimicking a heart attack after receiving the first dose of the mRNA COVID-19 vaccine. There were no known preceding cardiovascular risk factors. Workups were done, and the diagnosis made was unstable angina pectoris. This may remind physicians to increase awareness of cardiovascular side effects in this vaccination era, as it may be encountered even in younger patients. The patient was seen at Dr. Soetomo General Academic Hospital, Surabaya, Indonesia, in August 2022.


Asunto(s)
Angina Inestable , COVID-19 , Humanos , Masculino , Adulto , COVID-19/prevención & control , Vacunas contra la COVID-19/efectos adversos , SARS-CoV-2
2.
J Pak Med Assoc ; 74(6 (Supple-6)): S92-S95, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-39018149

RESUMEN

Percutaneous coronary intervention (PCI) on a proximal chronic total occlusion (CTO) of the right coronary artery (RCA) with concurrent ostial stenosis can be challenging because of the significant difficulty in properly engaging the catheter and providing stable support during the procedure. We report the case of a 57-year-old man with chronic coronary syndrome who underwent an elective PCI at the Dr. Soetomo General Hospital in Surabaya, on April 13th, 2022. At the beginning of the procedure, there was difficulty in intubating the RCA, which required the guide catheter replacement. The angiography revealed a significant lesion at the ostium, a CTO at proximal to mid- RCA with bridging collaterals, and a significant distal lesion. Several strategies to improve guiding catheter support during PCI are using large and supportive shape guide catheters, deep guide catheter intubation, extra support wire, microcatheter and guide catheter extension. The risk of pressure dampening and ischaemia upon engagement should always be kept under consideration.


Asunto(s)
Angiografía Coronaria , Oclusión Coronaria , Estenosis Coronaria , Intervención Coronaria Percutánea , Humanos , Masculino , Persona de Mediana Edad , Oclusión Coronaria/cirugía , Oclusión Coronaria/terapia , Intervención Coronaria Percutánea/métodos , Estenosis Coronaria/cirugía , Estenosis Coronaria/diagnóstico por imagen , Estenosis Coronaria/terapia , Estenosis Coronaria/complicaciones , Enfermedad Crónica , Vasos Coronarios/diagnóstico por imagen
3.
J Pak Med Assoc ; 74(6 (Supple-6)): S4-S8, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-39018131

RESUMEN

OBJECTIVE: To develop a cardiologic scoring system to predict mortality among geriatric coronavirus disease-2019 patients. METHODS: The retrospective cohort study was conducted after approval from the ethics review committee of the Dr Soetomo General Academic Hospital, Surabaya, Indonesia, and comprised data from March 1, 2020, to April 30, 2021, of geriatric patients of either gender confirmed for coronavirus disease-2019 from several referral hospitals in East Java, Indonesia. Data on comorbidities, electrocardiograph, and chest X-ray findings was examined to develop a comprehensive scoring system. Data was analysed using SPSS 26. RESULTS: Of the 3,893 cases reviewed, data of 322(8.27%) patients was analysed; 191(59.3%) males and 131(40.7%) females. The overall mean age was 66±4.1 years (range: 60-75 years). Of them, 267(82.9%) subjects were alive upon hospital discharge, while 55(17.1%) died during hospitalisation. Of the 24 variables analysed, 5(21%) were found to be significant: cardiomegaly, sinus tachycardia, ST-segment abnormalities, pathological T-wave inversions, and axis deviation (p<0.05). Receiver operating characteristic curve analysis showed an area under the curve 0.86, cut-off point ≤4 with sensitivity 89% and specificity 69%. CONCLUSIONS: The scoring system was found to have the potential to predict mortality in geriatric coronavirus disease-2019 patients based on cardiac findings during hospital admission.


Asunto(s)
COVID-19 , SARS-CoV-2 , Humanos , COVID-19/mortalidad , COVID-19/epidemiología , Femenino , Masculino , Anciano , Estudios Retrospectivos , Persona de Mediana Edad , Indonesia/epidemiología , Electrocardiografía , Comorbilidad , Curva ROC
4.
J Pak Med Assoc ; 74(6 (Supple-6)): S13-S17, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-39018133

RESUMEN

OBJECTIVE: To evaluate the factors associated with mortality among coronavirus disease-2019 patients with preexisting hypertension. METHODS: The retrospective, cross-sectional study was conducted from June 15 to July 7, 2021, after approval from Dr Soetomo General Province Hospital, Indonesia, and comprised data from the coronavirus disease-2019 registry in the East Java province of Indonesia from March 2020 to June 2021. Data was collected for adult patients infected by coronavirus disease-2019 with pre-existing hypertension Data was analysed using SPSS 23. RESULTS: Of the 2,732 patients in the registry, 425(15.6%) with median age 56.5 years (interquartile range: 50-64 years) had pre-existing hypertension. Of them, 251(59.06%) were males, and 110(25.9%) had died while in hospital. Mortality was associated with older age; higher white blood cell counts at admission and lower platelet count (p<0.05). In addition, electrocardiogram parameters associated with mortality were faster heart rate and ST abnormality (p<0.05). CONCLUSIONS: Older age, high white blood cell level, lower platelet count, faster heart rate, and ST abnormality at admission were found to be the predictors of mortality among hospitalised coronavirus disease-2019 patients with pre-existing hypertension.


Asunto(s)
COVID-19 , Electrocardiografía , Hipertensión , Pandemias , SARS-CoV-2 , Humanos , COVID-19/mortalidad , COVID-19/complicaciones , COVID-19/epidemiología , Masculino , Persona de Mediana Edad , Indonesia/epidemiología , Femenino , Hipertensión/epidemiología , Hipertensión/mortalidad , Hipertensión/complicaciones , Estudios Transversales , Estudios Retrospectivos , Infecciones por Coronavirus/mortalidad , Infecciones por Coronavirus/complicaciones , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/diagnóstico , Neumonía Viral/mortalidad , Neumonía Viral/complicaciones , Neumonía Viral/epidemiología , Neumonía Viral/diagnóstico , Betacoronavirus , Anciano , Factores de Edad , Adulto , Recuento de Leucocitos , Factores de Riesgo , Recuento de Plaquetas , Mortalidad Hospitalaria
5.
J Pak Med Assoc ; 74(6 (Supple-6)): S73-S76, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-39018144

RESUMEN

Wellens syndrome, an ST Elevation Myocardial Infarction (STEMI) equivalent, is also known as T-wave left anterior descending (LAD) coronary artery disease. Wellens syndrome is characterized by a unique electrocardiogram (ECG) pattern that suggests a significant stenosis in the left anterior descending coronary artery that warrants immediate intervention. Hereby, we present a case report of Wellens syndrome in a patient with a history of hypertension and chronic obstructive pulmonary disease (COPD) that may be potentially mistaken for pseudo- Wellens syndrome because the ECG pattern mimics left ventricular strain pattern (LVSP) in left ventricular hypertrophy (LVH). Thus, cautious examination of recent chest pain and ECG is important to differentiate Wellens syndrome and LVSP in patients with hypertension and COPD to perform early detection and aggressive intervention since they may help to lessen the adverse results.


Asunto(s)
Electrocardiografía , Hipertensión , Enfermedad Pulmonar Obstructiva Crónica , Humanos , Enfermedad Pulmonar Obstructiva Crónica/complicaciones , Enfermedad Pulmonar Obstructiva Crónica/fisiopatología , Hipertensión/complicaciones , Masculino , Infarto del Miocardio con Elevación del ST/diagnóstico , Infarto del Miocardio con Elevación del ST/fisiopatología , Infarto del Miocardio con Elevación del ST/complicaciones , Infarto del Miocardio con Elevación del ST/etiología , Persona de Mediana Edad , Hipertrofia Ventricular Izquierda/diagnóstico , Hipertrofia Ventricular Izquierda/fisiopatología , Hipertrofia Ventricular Izquierda/etiología , Diagnóstico Diferencial , Estenosis Coronaria/diagnóstico por imagen , Estenosis Coronaria/complicaciones , Estenosis Coronaria/diagnóstico , Estenosis Coronaria/fisiopatología , Dolor en el Pecho/etiología , Dolor en el Pecho/diagnóstico , Angiografía Coronaria , Síndrome
6.
J Pak Med Assoc ; 74(6 (Supple-6)): S34-S40, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-39018137

RESUMEN

OBJECTIVE: To review relevant literature regarding the role of metformin in angiogenesis among diabetic patients. METHODS: The systematic review and meta-analysis conducted from May to September 2022, and comprised search on Medline, ScienceDirect, ProQuest, Web of Science, EBSCOhost and Cochrane Library databases. The studies included were published in the English language and were human studies having angiogenesis endothelial markers as the outcomes of interest among patients of type 2 diabetes mellitus undergoing metformin therapy. Endothelial markers, including vascular endothelial growth factor, von-Willebrand-factor, plasminogen activator inhibitor-1, soluble vascular adhesion molecule- 1, intercellular adhesion molecule-1, soluble endothelialselectin, tissue plasminogen activator, urinary albumin excretion, platelet endothelial cell adhesion molecule-1 and thrombin-activatable fibrinolysis inhibitor, were assessed as angiogenesis outcomes. Data was statistically analysed using Review Manager 5.4. RESULTS: Of the 413 studies identified, 8(1.9%) were included; 5(62.5%) randomised control trials, 2(25.0%) cross-sectional, and 1(12.5%) cohort studies, with overall 1199 patients. Among the outcomes, von-Willebrandfactor (p=0.01), soluble vascular adhesion molecule-1 (p<0.00001), intercellular adhesion molecule-1 (p=0.0003), soluble endothelial-selectin (p=0.007), and tissue plasminogen activator (p<0.00001) showed significantly lower levels after metformin treatment using the random effect methods. CONCLUSIONS: Metformin was found to have an additional effect of endothelial function improvement.


Asunto(s)
Diabetes Mellitus Tipo 2 , Hipoglucemiantes , Metformina , Humanos , Metformina/uso terapéutico , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hipoglucemiantes/uso terapéutico , Inhibidor 1 de Activador Plasminogénico/sangre , Inhibidor 1 de Activador Plasminogénico/metabolismo , Factor A de Crecimiento Endotelial Vascular/metabolismo , Factor A de Crecimiento Endotelial Vascular/sangre , Selectina E/sangre , Molécula 1 de Adhesión Celular Vascular/sangre , Activador de Tejido Plasminógeno , Molécula 1 de Adhesión Intercelular/sangre , Molécula 1 de Adhesión Intercelular/metabolismo , Factor de von Willebrand/metabolismo , Angiogénesis
7.
J Pak Med Assoc ; 74(6 (Supple-6)): S57-S60, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-39018140

RESUMEN

Coronary artery fistula is a rare anomaly involving the coronary artery and a heart chamber or vessel. Percutaneous intervention has been shown to be effective and safe in fistulas that are small and nontortuous; however, it is not an absolute contraindication in fistulas that are large and tortuous. We report a delayed diagnosis of a single, large-diameter, tortuous coronary artery fistula that manifested as myocardial ischaemia due to the steal phenomenon in a 49 year old male. The undesirable connection was successfully obliterated by percutaneous embolisation, followed by an improvement in symptoms and daily activities. Steal phenomenon is the fundamental mechanism of myocardial ischaemia in coronary artery fistula, as confirmed by improvement in symptoms and coronary artery perfusion following occlusion of the fistula. Percutaneous catheterization is safe and effective for coronary artery fistula closure, and the occlusion site should be precise to achieve complete occlusion and prevent complications.


Asunto(s)
Embolización Terapéutica , Humanos , Masculino , Persona de Mediana Edad , Embolización Terapéutica/métodos , Anomalías de los Vasos Coronarios/terapia , Anomalías de los Vasos Coronarios/complicaciones , Anomalías de los Vasos Coronarios/diagnóstico por imagen , Angiografía Coronaria , Fístula Vascular/terapia , Fístula Vascular/diagnóstico por imagen , Isquemia Miocárdica/terapia , Isquemia Miocárdica/etiología , Cateterismo Cardíaco/métodos , Vasos Coronarios/diagnóstico por imagen
8.
BMC Cardiovasc Disord ; 23(1): 449, 2023 09 11.
Artículo en Inglés | MEDLINE | ID: mdl-37697278

RESUMEN

BACKGROUND: According to WHO 2020, CAD is the second leading cause of death in Indonesia with death cases reaching 259,297 or 15.33% of total deaths. Unfortunately, most of the patients of CAD in Indonesia did not match the golden period or decline to be treated with Percutaneous Coronary Intervention (PCI). Based on the recent study, there were increases in MMP-9, NOX2, and TGF-ß1 in STEMI patients which contribute to cardiac remodeling. Moreover, there is controversy regarding the benefit of late PCI (12-48 hours after onset of STEMI) in stable patients. Lately, colchicine is widely used in cardiovascular disease. This study was conducted to explore the effect of colchicine to reduce MMP- 9, NOX2, and TGF-ß1 levels after myocardial infarction in stable patients. METHOD: In this clinical trial study, we assessed 129 STEMI patients, about 102 patients who met inclusion criteria were randomized into four groups. Around 25 patients received late PCI (12-48 h after the onset of chest pain), optimal medical treatment (OMT) for STEMI, and colchicine; 24 patients received late PCI and OMT; 22 patients didn't get the revascularization (No Revas), OMT, and colchicine; and 31 patients received No Revas and OMT only. The laboratory test for MMP-9, NOX2, and TGF-ß1 were tested in Day-1 and Day-5. The data were analyzed using Mann-Whitney. RESULTS: A total of 102 patients with mean age of 56 ± 9.9, were assigned into four groups. The data analysis showed significant results within No Revas + OMT + Colchicine group versus No Revas + OMT + Placebo in MMP-9 (Day-1: p = 0.001; Day-5: p = 0.022), NOX2 (Day-1: p = 0.02; Day-5: p = 0.026), and TGF-ß1 (Day-1: p = 0.00; Day-5: p = 0.00) with the less three markers in OMT + Colchicine group than OMT + Placebo group. There were no significant differences within the late PCI + OMT + colchicine group and PCI + OMT + Placebo group. CONCLUSIONS: Colchicine could significantly reduce MMP-9, NOX2, and TGF-ß1 levels in stable STEMI patients. So that, colchicine could be a potential agent in STEMI patients and prevent cardiac remodeling events.


Asunto(s)
Colchicina , Infarto del Miocardio , Intervención Coronaria Percutánea , Infarto del Miocardio con Elevación del ST , Anciano , Humanos , Persona de Mediana Edad , Colchicina/uso terapéutico , Metaloproteinasa 9 de la Matriz , Infarto del Miocardio/diagnóstico , Infarto del Miocardio/tratamiento farmacológico , Infarto del Miocardio con Elevación del ST/diagnóstico , Infarto del Miocardio con Elevación del ST/tratamiento farmacológico , Factor de Crecimiento Transformador beta1 , Remodelación Ventricular
9.
World J Surg Oncol ; 21(1): 99, 2023 Mar 20.
Artículo en Inglés | MEDLINE | ID: mdl-36941612

RESUMEN

BACKGROUND: Cardiac myxoma is the most common type of primary cardiac tumor, with the majority located in the atrial wall. The tumor is attached to valvular structures in a few cases, of which the pulmonary valve is the least affected. Pulmonary valve myxoma may have different clinical manifestations from the more common cardiac myxomas because of its vital position. A misdiagnosis of these types of cardiac myxoma may be detrimental to the care and well-being of patients. Therefore, this systematic review aims to define the clinical characteristics of pulmonary valve myxoma and how this differs from a more common cardiac myxoma. METHODS: Employed literature was obtained from PubMed, ScienceDirect, Scopus, Springer, and ProQuest without a publication year limit on August 23, 2022. The keyword was "pulmonary valve myxoma." Inclusion criteria were as follows: (1) case report or series, (2) available individual patient data, and (3) myxoma that is attached to pulmonary valve structures with no evidence of metastasis. Non-English language or nonhuman subject studies were excluded. Johanna Briggs Institute checklists were used for the risk of bias assessment. Data are presented descriptively. RESULTS: This review included 9 case reports from 2237 articles. All cases show a low risk of bias. Pulmonary valve myxoma is dominated by males (5:4), and the patient's median age is 57 years with a bimodal distribution in pediatric and geriatric populations. The clinical manifestation of pulmonary valve myxoma is often unspecified or asymptomatic. However, systolic murmur in the pulmonary valve area is heard in 67% of cases. Echocardiography remains the diagnostic modality of choice in the majority of cases. Tumor attached to the pulmonary cusps or annulus and extended to adjacent tissues in all cases. Therefore, valve replacement or adjacent tissue reconstructions are required in 77% of cases. The recurrence and mortality are considerably high, with 33% and 22% cases, respectively. CONCLUSIONS: Pulmonary valve myxoma is more common in males with a bimodal age distribution, and its outcomes seem worse than usual cardiac myxomas. Increasing awareness of its clinical symptoms, early diagnosis, and complete myxoma resection before the presence of congestive heart failure symptoms are important in achieving excellent outcomes. A firm embolization blockade is needed to prevent myxoma recurrence.


Asunto(s)
Neoplasias Cardíacas , Mixoma , Válvula Pulmonar , Masculino , Humanos , Niño , Anciano , Persona de Mediana Edad , Válvula Pulmonar/cirugía , Válvula Pulmonar/patología , Ecocardiografía , Neoplasias Cardíacas/diagnóstico , Neoplasias Cardíacas/cirugía , Mixoma/diagnóstico , Mixoma/cirugía , Mixoma/patología , Atrios Cardíacos/patología
10.
Med Sci Monit ; 28: e935002, 2022 Mar 02.
Artículo en Inglés | MEDLINE | ID: mdl-35232953

RESUMEN

BACKGROUND This was a retrospective study conducted at a rural referral center in East Java, Indonesia, to evaluate the association between the platelet-to-lymphocyte ratio (PLR) on hospital admission and the incidence of new symptomatic heart failure (HF) within 6 months in patients with acute coronary syndrome (ACS). MATERIAL AND METHODS The study population consisted of all ACS patients who were hospitalized between 1 January and 31 December 2018 at a non-percutaneous coronary intervention-capable secondary referral hospital and came for a routine follow-up until 6 months afterwards. The diagnosis of new symptomatic HF was based on International Classification of Diseases 10th revision code I50.9. RESULTS From 126 hospitalized patients, 92 patients were included in the analysis. The incidence rate of new symptomatic HF at 6 months was 70.65%. High PLR upon initial admission was significantly associated with new symptomatic HF incidence (odds ratio=1.70, P<0.001). PLR was also able to discriminate new symptomatic HF incidence at 6 months with area under the curve of 0.83 (P=0.001). Multivariate Cox regression analysis showed that PLR was an independent predictor for new symptomatic HF incidence (hazard ratio=4.5, P=0.001). CONCLUSIONS In a rural center in Indonesia, the PLR was independently correlated with the onset of new symptomatic HF in patients with ACS 6 months after hospital admission. The PLR may be a supplementary biomarker for clinical outcomes in patients with ACS for use in resource-limited regions.


Asunto(s)
Síndrome Coronario Agudo/sangre , Insuficiencia Cardíaca/etiología , Hospitalización/tendencias , Población Rural/estadística & datos numéricos , Síndrome Coronario Agudo/complicaciones , Síndrome Coronario Agudo/epidemiología , Anciano , Biomarcadores/sangre , Femenino , Estudios de Seguimiento , Insuficiencia Cardíaca/diagnóstico , Insuficiencia Cardíaca/epidemiología , Humanos , Incidencia , Indonesia/epidemiología , Recuento de Linfocitos , Masculino , Persona de Mediana Edad , Recuento de Plaquetas , Pronóstico , Estudios Retrospectivos , Factores de Riesgo
11.
Acta Med Indones ; 52(1): 74-79, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-32291375

RESUMEN

Inhibition of the renin-angiotensin-aldosterone system (RAAS) is a key strategy in treating hypertension in cardiovascular and renal diseases. However, RAAS inhibitors (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aldosterone receptor antagonists, and direct renin inhibitors) increase the risk of hyperkalemia (serum potassium >5.5 mmol/L). This poses a therapeutic challenge because these patient groups comprise in whom the drugs are therapeutically indicated. Important considerations when initiating ACEI or ARB therapy include obtaining an estimate of glomerular filtration rate and a baseline serum potassium concentration, as well as assessing whether the patient has excessive potassium intake from diet, supplements, or drugs that can also increase serum potassium. Serum potassium monitoring shortly after initiation of therapy can assist in preventing hyperkalemia. If hyperkalemia does develop, prompt recognition of cardiac dysrhythmias and effective treatment to antagonize the cardiac effects of potassium, redistribute potassium into cells, and remove excess potassium from the body is important. Understanding the mechanism of action and monitoring of ACEI and ARB coupled with judicious drug use and clinical vigilance can minimize the risk to the patient of developing hyperkalemia.


Asunto(s)
Antagonistas de Receptores de Angiotensina/efectos adversos , Inhibidores de la Enzima Convertidora de Angiotensina/efectos adversos , Hiperpotasemia/inducido químicamente , Potasio/administración & dosificación , Insuficiencia Renal Crónica/fisiopatología , Dieta , Interacciones Alimento-Droga , Tasa de Filtración Glomerular/efectos de los fármacos , Humanos , Hiperpotasemia/sangre , Hiperpotasemia/terapia , Potasio/sangre , Insuficiencia Renal Crónica/tratamiento farmacológico , Sistema Renina-Angiotensina/efectos de los fármacos , Factores de Riesgo
12.
Mol Cell Biochem ; 400(1-2): 201-6, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25421411

RESUMEN

Endothelial progenitor cells (EPCs) clinical applications have been well reported. However, due to low number of EPCs that could be isolated, EPCs expansion study became one of the main focuses. Some optimized mediums to culture EPCs were currently available. However, the proliferation signaling pathway is not clearly disclosed yet. Peripheral blood was collected from eight healthy subjects, followed by mononuclear cells (MNCs) isolation. MNCs were then prepared and cultured for 2 days. After that, non-adherent cells were harvested and further cultured for 3 days. Resulted colony-forming unit (CFU)-Hill colonies were documented and enumerated under an inverted light microscope. To detect membrane markers, immunofluorescence was performed to detect CD34, VEGFR-2, and CD133. Cell documentation was conducted under a fluorescence microscope. To check cell proliferation, XTT Cell Proliferation Assay Kit was used according to kit insert. To detect possible activation of p44/42 MAPK, western blot was performed to detect p44/42 MAPK and phosphorylated p44/42 MAPK. All visualized bands were captured and quantified. Our results showed that EPCs markers (CD34, CD133 and VEGFR-2) were detected in 3 days culture. From XTT cell proliferation assay and CFU enumeration results, we found that EPCs proliferated significantly (p = 0.012) with addition of supplement. Phosphorylated-p42 MAPK expression of EPCs treated with supplement was significantly higher than the one of EPCs without treatment. Significant inhibition of p42 MAPK phosphorylation by U0126 was observed (p = 0.012). By pretreatment of U0126, number of viable cells and CFUs treated with supplement was significantly decreased (p = 0.012). Our results showed that MEK-dependent p42 MAPK pathway might play an important role in EPCs proliferation.


Asunto(s)
Diferenciación Celular/genética , Proliferación Celular/genética , Células Progenitoras Endoteliales , Proteína Quinasa 1 Activada por Mitógenos/biosíntesis , Adhesión Celular/genética , Movimiento Celular , Células Cultivadas , Regulación del Desarrollo de la Expresión Génica , Humanos , Sistema de Señalización de MAP Quinasas/genética , Masculino , Persona de Mediana Edad , Proteína Quinasa 1 Activada por Mitógenos/genética
13.
Curr Probl Cardiol ; 49(3): 102395, 2024 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-38232922

RESUMEN

The principal management of Amiodarone-induced-thyrotoxicosis (AIT) is balancing cardiac-thyroid conditions. However, the role of thyroidectomy is still contentious. This systematic review aims to provide insights into the roles of thyroidectomy in the management of AIT. This systematic review encompasses 303 AIT patients who underwent thyroidectomy from 14 studies. The indication of thyroidectomy can be due to cardiac factors, thyrotoxicosis conditions, and patient-physician considerations. Thyroidectomy is more effective in improving thyroid hormone status, cardiac function, and mortality compared to optimal medical therapy, especially in those with left ventricular ejection fraction < 40 %. Thyroidectomy is effective in improving cardiac function and mortality due to shorter duration for achieving euthyroid. Thyroidectomy and medical therapy have comparable side effects. However, the identification of high-risk patients may reduce thyroidectomy complications. Thus, thyroidectomy should not be viewed as the last resource and should be performed immediately when indicated.


Asunto(s)
Amiodarona , Antiarrítmicos , Tiroidectomía , Tirotoxicosis , Humanos , Tiroidectomía/métodos , Amiodarona/efectos adversos , Tirotoxicosis/inducido químicamente , Tirotoxicosis/cirugía , Antiarrítmicos/efectos adversos , Antiarrítmicos/uso terapéutico
14.
Curr Probl Cardiol ; 49(5): 102475, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38401823

RESUMEN

C-Reactive Protein (CRP)-albumin ratio (CAR) is a novel prognostic biomarker that is predicted to be a more reliable indicator than CRP or albumin alone. Therefore, this systematic review aimed to evaluate the role of CAR in predicting poor outcomes of heart failure (HF) patients. We conducted a literature search across ProQuest, PubMed, ScienceDirect, Web of Science, and Scopus. All related studies assessing CAR and reporting mortality outcomes or other adverse outcomes were assessed. A total of five studies with a total of 1821 patients were included in this review. CAR is significantly associated with all-causes in-hospital mortality and out-hospital mortality in patients with acute and chronic heart failure. CAR is associated with higher hospitalization rates, the number of hospitalizations, severe New York Heart Association (NYHA) classification, and the risk of advanced HF. In conclusion, CAR is significantly associated with poor HF outcomes including all-cause mortality (cardiac and non-cardiac death).


Asunto(s)
Proteína C-Reactiva , Insuficiencia Cardíaca , Humanos , Pronóstico , Albúminas , Insuficiencia Cardíaca/diagnóstico , Biomarcadores
15.
Eur J Surg Oncol ; 50(2): 107940, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-38219702

RESUMEN

Cardiac myxoma is the most common primary cardiac tumor. However, existing literature mainly consists of single-center experiences with limited subjects. This systematic review aimed to provide data on clinical characteristics and surgical outcomes of cardiac myxoma. We performed a thorough literature search on May 23, 2023 on PubMed, ProQuest, ScienceDirect, Scopus, and Web of Science. The inclusion criteria were English full-text, observational studies, and included >20 subjects. From the search, 112 studies with a total of 8150 patients were included in the analysis. The mean age was 51 years (95 % confidence interval [95%CI] = 49.1-52.3), and the majority were females (64.3 % [95 % CI = 62.8-65.8 %]). The most common clinical manifestation was cardiovascular symptoms. Echocardiography can diagnose almost all cases (98.1 % [95 % CI = 95.8-99.6 %]). Cardiac myxoma was mostly prevalent in left atrium (85.3 % [95%CI = 83.3-87 %]) and predominantly with pedunculated morphology (75.6 % [95%CI = 64.1-84.3 %]). Post-tumor excision outcomes were excellent, with an early mortality of 1.27 % (95 % CI = 0.8-1.8 %), late mortality rate of 4.7 (95 % CI = 2.5-7.4) per 1000 person-years, and recurrence rate at 0.5 (95 % CI = 0.0-1.1) per 1000 person-years. Tumor excision is warranted in a timely manner once the cardiac myxoma diagnosis is established.


Asunto(s)
Neoplasias Cardíacas , Mixoma , Femenino , Humanos , Persona de Mediana Edad , Masculino , Ecocardiografía , Atrios Cardíacos/cirugía , Atrios Cardíacos/patología , Neoplasias Cardíacas/diagnóstico , Neoplasias Cardíacas/epidemiología , Neoplasias Cardíacas/cirugía , Mixoma/diagnóstico , Mixoma/epidemiología , Mixoma/cirugía , Resultado del Tratamiento
16.
Curr Probl Cardiol ; 49(2): 102343, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-38103812

RESUMEN

The association between long-term systolic blood pressure variability (SBPV) and cardiovascular (CV) outcomes after being adjusted with mean blood pressure (BP) is questionable. This systematic review aims to evaluate the associations between mean BP adjusted long-term SBPV and CV outcomes. A systematic search was conducted on PubMed, Scopus, and Science Direct on January 4, 2023. A total of 9,944,254 subjects from 43 studies were included in this meta-analysis. Long-term SBPV increased the risk of all-cause mortality (HR 1.21 [95%CI 1.16-1.25], I2=100%), CV mortality (HR 1.10 [95%CI 1.07-11.4], I2 = 90%), MACE (HR 1.10 [1.07-1.13], I2 = 91%), cerebrovascular stroke (HR 1.22 [1.16-1.29], I2=100%), and myocardial infarction (HR 1.13 [95%CI (1.07-1.19)], I2=91%). European populations generally had higher risk compared to other continents. In conclusion, long-term SBPV is associated with all-cause mortality, CV mortality, MACE, MI, and stroke. Poor outcomes related to long-term SBPV seem more dominated by cerebrovascular than coronary events.


Asunto(s)
Infarto del Miocardio , Accidente Cerebrovascular , Humanos , Presión Sanguínea/fisiología , Infarto del Miocardio/etiología , Accidente Cerebrovascular/epidemiología , Accidente Cerebrovascular/etiología
17.
iScience ; 27(7): 110351, 2024 Jul 19.
Artículo en Inglés | MEDLINE | ID: mdl-39092174

RESUMEN

The presence of calcified nodule (CN) is a significant characteristic of atherothrombosis in acute coronary syndrome (ACS). However, its characteristics continue to be understudied. This review aimed to further investigate these characteristics. This study found that CN was a distinctive feature of an atheromatous plaque, representing 6.3% of ACS. CN was more common in NSTE-ACS than in STEMI patients (9.4% vs. 6.6%). CN was also chiefly observed in the left anterior descendant artery (48%), followed by the right coronary (40.4%) and left circumflex (14.5%) arteries. Higher prevalence of hypertension (78.8%), diabetes mellitus (50.8%), multivessel disease (71.7%), and kidney disease (26.43%) were noted in CN compared to non-CN patients. CN-associated ACS also 6-fold increased the risk of target lesion revascularization compared to those without CN.

18.
J Clin Med ; 13(2)2024 Jan 08.
Artículo en Inglés | MEDLINE | ID: mdl-38256486

RESUMEN

Background. Myocardial involvement among critically ill patients with coronavirus disease 2019 (COVID-19) often has worse outcomes. An imbalance in the oxygen supply causes the excessive release of pro-inflammatory cytokines, which results in increased ventilation requirements and the risk of death in COVID-19 patients. Purpose. We evaluated the association between the hs-troponin I levels and global longitudinal strain (GLS) as evidence of myocardial involvement among critical COVID-19 patients. Methods. We conducted a prospective cohort study from 1 February to 31 July 2021 at RSUD Dr. Soetomo, Surabaya, as a COVID-19 referral center. Of the 65 critical COVID-19 patients included, 41 (63.1%) were men, with a median age (interquartile range) of 51.0 years (20.0-75.0). Subjects were recruited based on WHO criteria for severe COVID-19, and myocardial involvement in the form of myocarditis was assessed using CDC criteria. Subjects were examined using echocardiography to measure the GLS, and blood samples were taken to measure the hs-troponin. Subjects were then followed for their need for mechanical ventilation and in-hospital mortality. Results. Severe COVID-19 patients with cardiac injury were associated with an increased need for intubation (78.5%) and an increased incidence of myocarditis (50.8%). There was a relationship between the use of intubation and the risk of death in patients (66.7% vs. 33.3%, p-value < 0.001). Decreased GLS and increased hs-troponin were associated with increased myocarditis (p values < 0.001 and 0.004, respectively). Decreased GLS was associated with a higher need for mechanical ventilation (12.17 + 4.79 vs. 15.65 + 4.90, p-value = 0.02) and higher mortality (11.36 + 4.64 vs. 14.74 + 4.82; p-value = 0.005). Elevated hs-troponin was associated with a higher need for mechanical ventilation (25.33% vs. 3.56%, p-value = 0.002) and higher mortality (34.57% vs. 5.76%, p-value = 0.002). Conclusions. Critically ill COVID-19 patients with myocardial involvement and elevated cardiac troponin levels are associated with a higher need for mechanical ventilation and higher mortality.

19.
Biomol Biomed ; 23(6): 936-948, 2023 Nov 03.
Artículo en Inglés | MEDLINE | ID: mdl-37337893

RESUMEN

Current research supports the evidence that the gut microbiome (GM), which consist of gut microbiota and their biologically active metabolites, is associated with atherosclerosis development. Trimethylamine-N-oxide (TMAO), a metabolite produced by the GM through trimethylamine (TMA) oxidation, significantly enhances the formation and vulnerability of atherosclerotic plaques. TMAO promotes inflammation and oxidative stress in endothelial cells, leading to vascular dysfunction and plaque formation. Dimethyl-1-butanol (DMB), iodomethylcholine (IMC) and fluoromethylcholine (FMC) have been recognized for their ability to reduce plasma TMAO by inhibiting trimethylamine lyase, a bacterial enzyme involved in the choline cleavage anaerobic process, thus reducing TMA formation. Conversely, indole-3-carbinol (I3C) and trigonelline inhibit TMA oxidation by inhibiting flavin-containing monooxygenase-3 (FMO3), resulting in reduced plasma TMAO. The combined use of inhibitors of choline trimethylamine lyase and flavin-containing monooxygenase-3 could provide novel therapeutic strategies for cardiovascular disease prevention by stabilizing existing atherosclerotic plaques. This review aims to present the current evidence of the roles of TMA/TMAO in atherosclerosis as well as its potential therapeutic prevention aspects.


Asunto(s)
Aterosclerosis , Liasas , Placa Aterosclerótica , Humanos , Células Endoteliales/metabolismo , Colina , Óxidos
20.
Heliyon ; 9(8): e18553, 2023 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-37576209

RESUMEN

Background: The shock index (SI) ratio serves as a straightforward predictor to identify patients who are either at risk of or experiencing shock. COVID-19 patients with shock face increased mortality risk and reduced chances of recovery. This review aims to determine the role of SI in the emergency department (ED) to predict COVID-19 patient outcomes. Methods: The systematic search was conducted in PubMed, ProQuest, Scopus, and ScienceDirect on June 16, 2023. We included observational studies evaluating SI in ED and COVID-19 patient outcomes. Random-effect meta-analysis was done to generate odds ratios of SI as the predictor of intensive care unit (ICU) admission and mortality. The sensitivity and specificity of SI in predicting these outcomes were also pooled, and a summary receiver operating characteristics (sROC) curve was generated. Results: A total of eight studies involving 4557 participants were included in the pooled analysis. High SI was found to be associated with an increased risk of ICU admission (OR 5.81 [95%CI: 1.18-28.58], p = 0.03). Regarding mortality, high SI was linked to higher rates of in-hospital (OR 7.45 [95%CI: 2.44-22.74], p = 0.0004), within 30-day (OR 7.34 [95%CI: 5.27-10.21], p < 0.00001), and overall (OR 7.52 [95%CI: 3.72-15.19], p < 0.00001) mortality. The sensitivity and specificity of SI for predicting ICU admission were 76.2% [95%CI: 54.6%-89.5%] and 64.3% [95%CI: 19.6%-93.0%], respectively. In terms of overall mortality, the sensitivity and specificity were 54.0% (95%CI: 34.3%-72.6%) and 85.9% (95%CI: 75.8%-92.3%), respectively, with only subtle changes for in-hospital and within 30-day mortality. Adjustment of SI cut-off to >0.7 yielded improved sensitivity (95%CI: 78.0% [59.7%-89.4%]) and specificity (95%CI: 76.8% [41.7%-93.9%]) in predicting overall mortality. Conclusion: SI in emergency room may be a simple and useful triage instrument for predicting ICU admission and mortality in COVID-19 patients. Future well-conducted studies are still needed to corroborate the findings of this study.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA